Policy & Medicine November 26, 2024
Thomas Sullivan

The Minnesota Department of Health recently unveiled a pivotal report on the 340B drug pricing program, which provides insight into how the program’s financial benefits are being utilized by non-profit hospitals and clinics. The 340B program was originally designed to help these facilities purchase medications at significantly reduced prices to support patient care for the underserved, the 340B program appears to be exploited for substantial financial gains that do not align with its intended goals.

Background and Implementation of the 340B Program

The 340B program was enacted in 1992 as part of the Public Health Service Act. It was intended to enable non profit healthcare organizations that serve high volumes of low-income patients to extend their federal resources further, enhancing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Health System / Hospital, Pharma, Pharma / Biotech, Provider, States, Survey / Study, Trends
Georgia Medicaid shakeup could force 3 in 4 beneficiaries to change plans: Centene CEO
Providence’s Joint Venture With Compassus Likely Delayed Amid Concerns About Patient Care And Rural Access
Multisector Plan for Aging Learning Collaborative
CMS taps 4 states for behavioral innovation model: 5 things to know
UCSD Health, county end plans for behavioral health hub

Share This Article